- Email: [email protected]
A study on percutaneous coronary intervention with long length (48 mm) Everolimus eluting stent
G Model
JICC-377; No. of Pages 1 Journal of Indian College of Cardiology xxx (2017) xxx–xxx
Contents lists available at ScienceDirect
Journal of Indian College of Cardiology journal homepage: www.elsevier.com/locate/jicc
Abstract
A study on percutaneous coronary intervention with long length (48 mm) Everolimus eluting stent Sridhar Kasthuri *, Shailender Singh, Narasaraju Kavalapati, Premchand Madarametla, Sharad Annam, Anil Krishna Gundala, Nitin Annarapu, Sridhar Papani, Rakendra Singh, Srinivasa Polasa, Swalehin Bux, Vinoth Kumar Vilvanathan, Shiva Kumar Bandmida, Manikandhar Pendyala, Chadrashekar Challa, Naveen
Background: Treatment with long length drug eluting stent (DES) reduces angiographic restenosis and need for repeat revascularization procedures. In this study a 3 month follow-up after successful implantation of Everolimus eluting stent showed good procedural and clinical outcomes in all percutaneous coronary intervention (PCI) population. Methods: The study population included a registry of 120 patients who underwent single or multi-vessel revascularization with clinical presentations such as stable angina and acute coronary syndrome in period between May 2014 and June 2015. All the patients enrolled were implanted with at least one 48 mm Everolimus eluting stent. The primary clinical endpoints were target lesion failure (TLF) as any cardiac death, target vessel myocardial infarction (MI), and target lesion revascularization (TLR). Secondary endpoint includes stent thrombosis (definite and probable events). Major adverse cardiac events (MACE) as a composite endpoint includes mortality, myocardial infarction, target lesion revascularization, target vessel and non-target vessel revascularization. Incidence of clinical outcomes was followed up through a 3 month period.
* Corresponding author. http://dx.doi.org/10.1016/j.jicc.2016.11.065 1561-8811/
Results: Overall 120 patients with 311 lesions were enrolled in the study with a mean age of 57.9 9.9 years and diabetic prevalence of 60%. The mean lesion length was 36.7 6 mm with mean reference vessel diameter 3.01 0.33 mm. Target lesion failure as a primary endpoint was significantly less, i.e., 5.0% which includes 5 cardiac deaths (4.2%) (2 in hospital deaths presented and stent thrombosis presented as MI; 3 follow-up deaths presented with MI, severe LV dysfunction; bleeding and stent thrombosis presented as death); and a case of clinically driven target lesion revascularization, i.e., 0.8%. MACE as a composite outcome on 3 month follow up is 5.0%. Conclusion: Positive impact on procedural and clinical outcomes on implantation of 48 mm Everolimus eluting stent makes it clear that it can be used in contemporary clinical practice and certainly in diffuse diseases in patients with diabetes where restenosis and long lesions are frequently seen. Conflicts of interest The authors have none to declare.
JICC-377; No. of Pages 1 Journal of Indian College of Cardiology xxx (2017) xxx–xxx
Contents lists available at ScienceDirect
Journal of Indian College of Cardiology journal homepage: www.elsevier.com/locate/jicc
Abstract
A study on percutaneous coronary intervention with long length (48 mm) Everolimus eluting stent Sridhar Kasthuri *, Shailender Singh, Narasaraju Kavalapati, Premchand Madarametla, Sharad Annam, Anil Krishna Gundala, Nitin Annarapu, Sridhar Papani, Rakendra Singh, Srinivasa Polasa, Swalehin Bux, Vinoth Kumar Vilvanathan, Shiva Kumar Bandmida, Manikandhar Pendyala, Chadrashekar Challa, Naveen
Background: Treatment with long length drug eluting stent (DES) reduces angiographic restenosis and need for repeat revascularization procedures. In this study a 3 month follow-up after successful implantation of Everolimus eluting stent showed good procedural and clinical outcomes in all percutaneous coronary intervention (PCI) population. Methods: The study population included a registry of 120 patients who underwent single or multi-vessel revascularization with clinical presentations such as stable angina and acute coronary syndrome in period between May 2014 and June 2015. All the patients enrolled were implanted with at least one 48 mm Everolimus eluting stent. The primary clinical endpoints were target lesion failure (TLF) as any cardiac death, target vessel myocardial infarction (MI), and target lesion revascularization (TLR). Secondary endpoint includes stent thrombosis (definite and probable events). Major adverse cardiac events (MACE) as a composite endpoint includes mortality, myocardial infarction, target lesion revascularization, target vessel and non-target vessel revascularization. Incidence of clinical outcomes was followed up through a 3 month period.
* Corresponding author. http://dx.doi.org/10.1016/j.jicc.2016.11.065 1561-8811/
Results: Overall 120 patients with 311 lesions were enrolled in the study with a mean age of 57.9 9.9 years and diabetic prevalence of 60%. The mean lesion length was 36.7 6 mm with mean reference vessel diameter 3.01 0.33 mm. Target lesion failure as a primary endpoint was significantly less, i.e., 5.0% which includes 5 cardiac deaths (4.2%) (2 in hospital deaths presented and stent thrombosis presented as MI; 3 follow-up deaths presented with MI, severe LV dysfunction; bleeding and stent thrombosis presented as death); and a case of clinically driven target lesion revascularization, i.e., 0.8%. MACE as a composite outcome on 3 month follow up is 5.0%. Conclusion: Positive impact on procedural and clinical outcomes on implantation of 48 mm Everolimus eluting stent makes it clear that it can be used in contemporary clinical practice and certainly in diffuse diseases in patients with diabetes where restenosis and long lesions are frequently seen. Conflicts of interest The authors have none to declare.